Status: Recruiting
SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding event (BE), or who are not on prophylactic treatment who may need to control a BE.
Participants needed: 55
Trial details
Phase: Phase 4Age: 12-100Biological sex: AllType: InterventionalSponsor: American Thrombosis and Hemostasis NetworkUpdated: Jan 12, 2026Locations: 21
Eligibility criteria
Have a diagnosis of hemophilia A or B with inhibitors. [+5]
Have a disorder of hemostasis in addition to Hemophilia A or B [+8]